Flavia Venetucci Gouveia

Has grant

Scientist

Hospital for Sick Children
Country flagCanada

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Investigation of the mechanisms of Deep Brain Stimulation for the treatment of Epilepsy in the PTZ-kindled mouse model

Open Date: 2022-04-01

Close Date:

Grant: Close

Investigation of Deep Brain Stimulation of the Habenula in a transgenic mouse model of Fragile X syndrome and autism spectrum disorder.

Open Date: 2021-11-01

Close Date:

Grant: Close

Towards revealing aggression: imaging the aggressive brain

Open Date: 2017-08-01

Close Date: 2017-11-01

Grant: Close

24 months of follow-up after partial bilateral amygdala lesion in patients with refractory aggressive behaviour.

Open Date: 2017-06-01

Close Date: 2017-06-01

Grant: Close

Insights about amygdala and aggression

Open Date: 2015-11-01

Close Date: 2015-11-01

Articles (15)

Year:

2026

Year:

2025

Year:

2025

Morphometric measures in humans derived from magnetic resonance imaging (MRI) have provided important insights into brain differences and changes associated with development and disease in vivo. Deformation-based morphometry (DBM) is a registration-based technique that has been shown to be useful in detecting local volume differences and longitudinal brain changes while not requiring a priori segmentation or tissue classification. Typically, DBM measures are derived from registration to common template brain space (one-level DBM). Here, we present a two-level DBM technique: first, the Jacobian determinants are calculated for each individual input MRI at the subject level to capture longitudinal individual brain changes; then, in a second step, an unbiased common group space is created, and the Jacobians co-registered to enable the comparison of individual morphological changes across subjects or groups. This two-level DBM is particularly suitable for capturing longitudinal intra-individual changes in vivo, as calculating the Jacobians within-subject space leads to superior accuracy. Using artificially induced volume differences, we demonstrate that this two-level DBM pipeline is 4.5x more sensitive in detecting longitudinal within-subject volume changes compared to a typical one-level DBM approach. It also captures the magnitude of the induced volume change much more accurately. Using 150 subjects from the OASIS-2 dataset, we demonstrate that the two-level DBM is superior in capturing cortical volume changes associated with cognitive decline across patients with dementia and cognitively healthy individuals. This pipeline provides researchers with a powerful tool to study longitudinal brain changes with superior accuracy and sensitivity. It is publicly available and has already been used successfully, proving its utility.

Year:

2025

Year:

2025

Nonsuicidal self-injurious behaviour (SIB) is a debilitating manifestation of physical aggression commonly observed across neurodevelopmental, psychiatric, and genetic disorders. This behaviour arises from a multifactorial aetiology involving genetic predispositions, epigenetic modifications, neurotransmitter dysregulation, and environmental stressors. Dysregulation in dopaminergic, serotonergic, glutamatergic, and GABAergic systems has been implicated in the pathophysiology of SIB, alongside structural and functional abnormalities within fronto-limbic-striatal circuits. These disruptions impair key processes, such as emotional regulation, reward processing, and behavioural inhibition, contributing to the emergence and reinforcement of SIB. Advances in preclinical research using genetic, lesion-based, pharmacological, and environmental animal models have been instrumental in elucidating the molecular and neurocircuitry underpinnings of SIB. Emerging neuromodulation therapies targeting critical nodes within the fronto-limbic-striatal network, particularly deep brain stimulation, have shown promise in treating severe, refractory SIB and improving quality of life. This review integrates current evidence from clinical studies, molecular research, and preclinical models to provide a comprehensive overview of the pathophysiology of SIB and therapeutic approaches. By focusing on the molecular mechanisms and neural circuits underlying SIB, we highlight the translational potential of emerging pharmacological and neuromodulatory therapies. A deeper understanding of these pathways will pave the way for precision-based interventions, bridging the gap between molecular research and clinical applications in SIB and related conditions.

Year:

2025

Year:

2024

Year:

2024

Deep brain stimulation (DBS) modulates local and widespread connectivity in dysfunctional networks. Positive results are observed in several patient populations; however, the precise mechanisms underlying treatment remain unknown. Translational DBS studies aim to answer these questions and provide knowledge for advancing the field. Here, we systematically review the literature on DBS studies involving models of neurological, developmental and neuropsychiatric disorders to provide a synthesis of the current scientific landscape surrounding this topic. A systematic analysis of the literature was performed following PRISMA guidelines. 407 original articles were included. Data extraction focused on study characteristics, including stimulation protocol, behavioural outcomes, and mechanisms of action. The number of articles published increased over the years, including 16 rat models and 13 mouse models of transgenic or healthy animals exposed to external factors to induce symptoms. Most studies targeted telencephalic structures with varying stimulation settings. Positive behavioural outcomes were reported in 85.8% of the included studies. In models of psychiatric and neurodevelopmental disorders, DBS-induced effects were associated with changes in monoamines and neuronal activity along the mesocorticolimbic circuit. For movement disorders, DBS improves symptoms via modulation of the striatal dopaminergic system. In dementia and epilepsy models, changes to cellular and molecular aspects of the hippocampus were shown to underlie symptom improvement. Despite limitations in translating findings from preclinical to clinical settings, rodent studies have contributed substantially to our current knowledge of the pathophysiology of disease and DBS mechanisms. Direct inhibition/excitation of neural activity, whereby DBS modulates pathological oscillatory activity within brain networks, is among the major theories of its mechanism. However, there remain fundamental questions on mechanisms, optimal targets and parameters that need to be better understood to improve this therapy and provide more individualized treatment according to the patient’s predominant symptoms.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (9)

Brian Nieman

Associate Professor

University of Toronto

CANADA
View details

Alfonso Fasano

Humanitas University

ITALY
View details

Gabriel Devenyi

Affilate

McGill University

CANADA
View details

George M. Ibrahim

-

CANADA
View details

Karim Mithani

University of Toronto

CANADA
View details

Nebras Warsi

Assistant Professor

Arkansas Children's Hospital

UNITED STATES
View details

Clement Hamani

Sunnybrook Research Institute

CANADA
View details

Harriet Lea-Banks

Lecturer

University College London

UNITED KINGDOM
View details

Jacob Ellegood

Research Associate

Hospital for Sick Children

CANADA
View details